Abstract
Non-alcoholic fatty liver disease (NAFLD), includes a spectrum of pathological conditions, from simple liver steatosis, to non-alcoholic steatohepatitis, to cirrhosis, with its various complications. NAFLD is closely associated with insulin resistance and with rapidly increasing incidence of obesity, it is quickly becoming the most common chronic liver condition, and not just in the western world.
Furthermore, NAFLD has significant liver-related and cardiovascular morbidity and mortality. NAFLD diagnostics consist of ruling out other possible liver diseases, and of efforts to non-invasively quantify liver fibrosis.
Weight reduction and increased physical activity remain an essential therapeutic measure. There is currently no known causal pharmacotherapy.